Trends in Risk Factors for Mother-to-Child Transmission of Hepatitis C Among a Southern European Population
EPIALHICE B
Trends in Risk of Mother-to-child Transmission of Hepatitis C Through Analysis of Prevalence of Risk Factors for Maternal Infection Among a Southern European Population
1 other identifier
observational
142
1 country
3
Brief Summary
According to the centres taking part in the ALHICE survey, the number of HIV-HCV co-infected women is currently decreasing. This drop was first noted in 2006 and persisted in 2007. What might have been considered a chance phenomenon during the first year (2006) was confirmed in the beginning of 2008. In view of this information, the investigators wished to ascertain the reality of this trend and to investigate its causes, by attempting to answer the following questions: - Has the prevalence of risk factors for HCV infection changed among the general population over the past 10 years?
- Has the prevalence of risk factors for HCV infection changed among HIV/HCV co-infected women over the past 10 years?
- Is the change in the number of co-infected women who gave birth during the past 10 years related to the prevalence of certain risk factors among this population?
- Is the change in the number of co-infected women who gave birth during the past 10 years related to a decrease in certain risk factors for HCV infection among the general population?
- Have changes in addictive behaviour among women of child-bearing age played a role in the decreasing number of HCV-contaminated children? Furthermore, follow-up data from HCV-infected children born during this period will provide information concerning the course of HCV infection. The objectives are to study trends in numbers of deliveries among HCV/HIV co-infected women as well as trends in risk factors for HCV infection among women of child bearing age and lastly to create a cohort of HCV infected children.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2009
Longer than P75 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 5, 2009
CompletedFirst Posted
Study publicly available on registry
May 6, 2009
CompletedStudy Start
First participant enrolled
May 25, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 15, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
April 15, 2014
CompletedNovember 13, 2023
November 1, 2023
4.9 years
May 5, 2009
November 9, 2023
Conditions
Keywords
Study Arms (1)
HCV/HIV infected pregnant women
Eligibility Criteria
HCV/HIV infected pregnant women
You may qualify if:
- Infected HIV/HCV pregnant women
- All women to give birth in 1 randomized week each 6 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
CHU Montpellier
Montpellier, 34000, France
CHU Nice
Nice, 06000, France
CHU Toulouse
Toulouse, 31000, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Eugénia MARINE-BARJOAN, MD
Centre Hospitalier Universitaire de Nice
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
May 5, 2009
First Posted
May 6, 2009
Study Start
May 25, 2009
Primary Completion
April 15, 2014
Study Completion
April 15, 2014
Last Updated
November 13, 2023
Record last verified: 2023-11